AbCellera Biologics Stock (NASDAQ:ABCL), Analyst Ratings, Price Targets, Predictions

The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Benchmark on February 22, 2024. The analyst firm set a price target for $0.00 expecting ABCL to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Benchmark, and AbCellera Biologics upgraded their buy rating.

The last upgrade for AbCellera Biologics Inc happened on February 22, 2024 when Benchmark raised their price target to N/A. Benchmark previously had a hold for AbCellera Biologics Inc.

There is no last downgrade for AbCellera Biologics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on February 22, 2024 so you should expect the next rating to be made available sometime around February 22, 2025.

While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a upgraded with a price target of $0.00 to $0.00. The current price AbCellera Biologics (ABCL) is trading at is $3.68, which is out of the analyst’s predicted range.